Last updated: March 2026
Most peptides are destroyed by stomach acid before reaching the bloodstream. But a handful of ultra-short peptides (2–3 amino acids) can survive digestion. Here's the science behind which route works for which peptides — and why.
Peptides are chains of amino acids. The longer the chain, the more peptide bonds there are to break — and the more opportunity the GI tract has to destroy them before they reach the bloodstream.
Stomach acid operates at pH 1.5–3.5. Proteolytic enzymes (pepsin in the stomach, trypsin and chymotrypsin in the small intestine) are specifically designed to break peptide bonds. For a 15-amino acid peptide like BPC-157, there are 14 peptide bonds to attack. For a 43-amino acid peptide like TB-500, there are 42. The GI tract is extraordinarily efficient at hydrolyzing peptides — it's literally what digestion is designed to do. The result: oral bioavailability of most research peptides approaches zero.
Novo Nordisk spent years engineering oral semaglutide (Rybelsus). Their solution was SNAC — sodium N-[8-(2-hydroxybenzoyl)amino]caprylate. SNAC is co-formulated with semaglutide and temporarily raises local gastric pH around the tablet, reducing pepsin activity. The result: ~1% bioavailability. This sounds terrible — but semaglutide is so potent that 1% of a 14mg tablet delivers enough drug. Still requires fasting for 30 minutes before and after dosing for even this marginal absorption. A remarkable engineering achievement for very modest bioavailability.
Di- and tripeptides (2–3 amino acids) can survive the GI tract via the PepT1 intestinal transporter — a channel designed to absorb di/tripeptides from food. KPV (Lys-Pro-Val), a tripeptide from α-MSH, exploits this pathway and demonstrates oral bioavailability in colitis models (Gastroenterology 2008, PMC2431115). Khavinson bioregulators (Epitalon AEDG, Pinealon EDR, Vesugen KED) are all designed as oral ultra-short peptides for precisely this reason. The 2–3 amino acid threshold is the critical boundary.
Subcutaneous and intramuscular injection bypass the entire GI problem. The peptide is deposited directly in tissue or muscle, where it diffuses into capillaries without encountering stomach acid or digestive enzymes. SubQ injection achieves 95%+ bioavailability for most peptides. The only losses are from tissue binding, enzymatic degradation in blood, and first-pass processing — much more manageable. Precise dosing, reliable absorption, and no GI side effects from absorption manipulation make injection the gold standard for longer peptides.
Approximate bioavailability ranges by administration route. Values vary by specific peptide, molecular weight, and formulation.
These are general ranges. Specific peptides may behave differently based on molecular weight, charge, lipophilicity, and any formulation modifications. The values reflect the general pharmacokinetic behavior of peptides in each category, not absolute numbers for any single compound.
A full comparison of all routes — bioavailability, best use cases, and drawbacks for each.
| Route | Bioavailability | Best For | Drawbacks |
|---|---|---|---|
| SubQ Injection | 95%+ | Most peptides (BPC-157, TB-500, semaglutide, GLP-1 class) | Needle fear, requires sterile technique, injection site rotation |
| Intramuscular | 85–95% | Vaccines, some depot formulations, certain peptides | Deeper injection, more discomfort, muscle tissue damage risk |
| Nasal Spray | 10–30% | Some small peptides, experimental PT-141 use | Variable absorption, mucosal irritation, nasal tolerance |
| Oral (Tripeptides) | Variable | KPV, Khavinson bioregulators (Epitalon, Pinealon), short-chain only | Only works for 2–3 amino acid chains — most peptides are too long |
| Oral (Engineered) | ~1% | Semaglutide (Rybelsus) only — requires SNAC carrier technology | Massive dose required, fasting, GI side effects, complex timing protocol |
| Topical | Local only | GHK-Cu in cosmeceuticals, wound dressings, skin applications | No systemic circulation — cosmetic/local effect only |
| Oral (Longer Peptides) | ~0% | Not viable for systemic use | Completely destroyed by stomach acid and proteolytic enzymes |
The short list of peptides with documented oral bioavailability — all 2–3 amino acids in length.
Tripeptide derived from the C-terminus of α-MSH. PepT1-mediated intestinal uptake. Anti-inflammatory activity demonstrated in DSS-induced colitis model with oral administration (Gastroenterology 2008, PMC2431115). Makes KPV unique — it's one of the only peptides in common research use with verified oral route efficacy.
Epitalon (AEDG), Pinealon (EDR), Vesugen (KED), and the other Khavinson ultra-short peptides are all designed as oral agents. Their 4-amino acid or shorter design is deliberate — short enough to resist GI degradation and utilize peptide transporters. This is why they're sold as oral capsules in Russian pharmaceutical formulations (Endoluten, Cortexin, etc.).
The PepT1 transporter exists to absorb dietary di/tripeptides — this is normal protein digestion biology. Research peptides that are 2–3 amino acids in length are essentially exploiting the same transporter that handles your food protein fragments. The transporter has broad substrate specificity, which is why short research peptides can piggyback on this pathway.
BPC-157 is 15 amino acids — outside the tripeptide oral threshold. However, some researchers note it was originally derived from gastric juice and may have unusual GI stability. Some animal studies use oral BPC-157 for GI-local effects (colitis, ulcer healing) where local GI exposure is the goal rather than systemic bioavailability. This doesn't mean it works orally for systemic indications — the distinction between GI-local and systemic effects is important.
Supplies for both injectable and oral peptide research.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It is not medical advice. Research peptides discussed on this page are NOT approved by the FDA for human therapeutic use. Semaglutide (Rybelsus/Ozempic/Wegovy) is FDA-approved but requires a prescription. Bioavailability values are general pharmacokinetic estimates from the scientific literature — individual results vary significantly based on formulation, individual physiology, and specific compound. Always consult a qualified healthcare provider before making any decisions about peptide administration. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.